<?xml version="1.0" encoding="UTF-8"?>
<p>The activity of hepatic enzymes such as ALP, AST, SGPT, SGOT, and renal functions such as serum creatinine in normal control group, diabetic control group and compound treatment group have been shown in 
 <xref ref-type="fig" rid="molecules-26-00137-f003">Figure 3</xref>. STZ-induced Diabetes in rat considerably increased (
 <italic>p</italic> &lt; 0.001) the level of liver marker enzymes such as SGPT, SGOT and ALP and renal functions such as serum creatinine and blood urea as compared to the normal control. Administration of standard glibenclamide (5 mg/kg) and CTN (2, 5, 10, 15, 30, and 50 mg/kg body weight) to diabetic rats resulted in significant decrease (
 <italic>p</italic> &lt; 0.01, 
 <italic>p</italic> &lt; 0.001) in ALP, AST, SGPT, SGOT, serum creatinine, and blood urea levels.
</p>
